Skip to main content Accessibility help
×
Home

Vancomycin-Resistant Enterococci in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1999–2005

  • Marianna Ofner-Agostini (a1), B. Lynn Johnston (a2), Andrew E. Simor (a3), John Embil (a4), Anne Matlow (a5), Michael Mulvey (a6), Debbie Ormiston, John Conly (a7) and Canadian Nosocomial Infection Surveillance Program...

Abstract

Surveillance for vancomycin-resistant enterococci (VRE) in sentinel Canadian hospitals has been conducted since 1999. From 1999 to 2005, the rate of VRE detection increased from 0.37 to 1.32 cases per 1,000 patients admitted, and the rate of VRE infection increased from 0.02 to 0.05 cases per 1,000 patients admitted. Thirty-three percent of all patients with VRE detected that were reported during 1999-2005 were identified in 2005, with increases seen in all regions of Canada. Although the incidence rate of VRE carriage in Canada is increasing, it remains very low.

Copyright

Corresponding author

Queen Elizabeth II Health Sciences Centre, Room 5014, Dickson Building, 1278 Tower Road, Halifax, NS, B3H 2Y9, Canada (ljohnsto@dal.ca)

References

Hide All
1.Chang, S, Sievert, DM, Hageman, JC, et al.Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:12421247.
2.Ofner-Agostini, ME, Conly, J, Paton, S, et al.Vancomycin-resistant enterococci (VRE) in Canada—results of the Canadian Nosocomial Infection Surveillance Program 1996: VRE point prevalence surveillance project. Can J Infect Dis 1997;8:7378.
3.National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1990– May 1999, issued June 1999. Am J Infect Control 1999;27:520532.
4.Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128140.
5.Ofner-Agostini, M, Varia, M, Johnston, L, et al.Infection control and antimicrobial restriction practices for antimicrobial resistant organisms (AROs) in Canadian tertiary care hospitals. Am J Infect Control 2007;35:563568.
6.Muto, CA, Jernigan, JA, Ostrowsky, BE, et al.SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:362386.
7.Simor, AE, Ofner-Agostini, M, Gravel, D, et al.; Canadian Hospital Epidemiology Committee; Canadian Nosocomial Infection Surveillance Program, Public Health Agency of Canada. Surveillance for mefhicillin-resistant Staphylococcus aureus in Canadian hospitals—a report update from the Canadian Nosocomial Infection Surveillance Program. Can Commun Dis Rep 2005;31:3340. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/05pdf/cdr3103.pdf. Accessed January 28, 2008.
8.Johnston, BL, Conly, JM. Clostridium difficile: the evolving story. Can J Infect Dis Med Microbiol 2007;18:341345.
9.Johnston, L, Ofner-Agostini, ME, Holton, D, et al.Laboratory and infection control protocols for vancomycin-resistant enterococci (VRE): a survey of CHEC facilities. In: 67th Conjoint Meeting on Infectious Diseases; October 31–November 4, 1999; Edmonton, Alberta, Canada. Abstract P49.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed